Expert discussions are underway on the lifting of bans on cannabis-derived drugs in Japan. The government is set to create the environment needed to allow for the utilization of such medicines by embracing this policy in its annual “honebuto” paper,…
HOME > TRENDS
TRENDS
-
Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
-
Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
-
“Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
-
Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
-
As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
-
Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
-
Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
-
Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
-
Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
-
Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
March 30, 2018
-
Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
-
Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
-
With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
February 8, 2018
-
Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
-
21 Drug Makers Expect 1.6% Increase in Sales but Decline in Profits in FY2017
November 15, 2017
-
Japan’s “NDB” Insurance Claim Database Corroborates Slack SGLT-2 Prescriptions for Older People in FY2015
September 26, 2017
-
Japan’s 1st DPP-4/SGLT-2 Pair to Hit Shelves Shortly, Will Shift to Combo Drugs Gain Ground?
September 5, 2017
-
Japan Generic Market Decelerating, 3 Majors Log Only Slight Uptick in April-June
August 22, 2017
ページ
“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…